Blog

The latest thoughts from Medicines Law & Policy partners.

The European Commission’s proposal on a new EU-wide compulsory licensing regime

Guest author Olga Gurgula is a Senior Lecturer in Intellectual Property Law at Brunel Law School, Brunel University London A recent international health emergency, the...

Medicines Law & Policy welcomes WHO’s Solidarity Call to Action to realise equitable global...

The World Health Organization today with Costa Rica launched the "COVID-19 Technology Access Pool (C-TAP)" to ensure that knowledge, data and intellectual property are...

Dutch health insurance company Menzis takes AstraZeneca to court over patent evergreening

Today health insurance company Menzis announced  that it is taking the pharmaceutical company AstraZeneca to court over the pricing of Seroquel, a medicine...

Strong call for transparency on medicine prices, cost of R&D at WHO Fair Pricing...

“Medical innovation has little social value if most people cannot access its benefits…. this is a global human rights issue,” said Mariângela Simão, Assistant...

Decision on intellectual property waiver over Covid technology on hold till 2021; what are...

Note: This article was edited on 19 December to include a statement from the EU supporting sharing of intellectual property, technology, and know-how transfer. The...

Wrapping up 2024: Noteworthy events in medicines law and policy around the globe

Welcome to Medicines Law & Policy’s  end of the year blog, our highly biased annual overview of memorable medicines law and policy events. January At the...

2018 Round-up of Noteworthy Medicines Law and Policy Events

We are reaching the end of 2018: Time for our end-of-the-year roundup of some significant developments in medicines law and policy. January The Chilean parliament started...

Written remarks submitted to the OHCHR following the Expert Workshop on the key challenges...

This blog was submitted by Dr. Katrina Perehudoff, Law Centre for Health and Rights at the University of Amsterdam, and Medicines Law & Policy,...

How not to solve a crisis: The European Commission’s Plan for Transferable Data Exclusivity...

Drug-resistant infections, sometimes called “superbugs,” killed an estimated 1.27 million people in 2019, a number set to rise to 50 million by 2050. It is...

Wrapping up 2023 with some noteworthy medicines, law and policy developments

Welcome to our 2023 end-of-the-year blog, our annual and highly-biased run-through of notable access to medicines events of the year that is about to...